11th Annual Tumor Models Boston Summit

Paid

The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encouraged the biopharmaceutical industry to shift away from animal models, allowing for more innovation in p

12-13 July 2023

Healthcare

Preclinical and Translational Immuno-Oncology

Paid

Advances in harnessing the immune system for therapeutic development have resulted in a robust pipeline of immuno-oncology therapies and novel combinations. A successful program requires appropriate models and tools for preclinical evaluation and effective strategies for translation. Our expert speakers will discuss choosing the right preclinical m

08-09 August 2023

Healthcare